Kabra Drugs Peer Comparison

BSE: 524322

₹20.49

₹-0.44 (-2.10%)

As on 27-Aug-2026IST

Market cap

₹49 Cr

Revenue (TTM)

₹132 Cr

P/E Ratio

6.4

P/B Ratio

1.5

Div. Yield

0 %

Edit

	Kabra Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	49	31,863	30,485	28,611	27,284
Revenue (₹ Cr)	132	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	7.59	414.00	288.22	-371.81	387.35
Net Margin (%)	5.73	11.23	14.79	-3.93	26.01
RoE (%)	27.30	8.38	29.77	-3.85	25.18
Price to Earnings	6.40	77.90	105.77	--	70.64
Price-To-Book	1.53	6.33	22.71	3.57	15.78

Income Statement (₹ Cr)

	Kabra Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	131.81	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	132.36	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	123.21	2,792.00	1,485.56	8,195.15	919.25
EBITDA	8.60	772.00	450.24	1,010.13	542.56
Depreciation	0.06	226.00	50.83	857.51	37.68
EBIT	8.53	546.00	399.41	152.62	504.88
Interest	0.02	217.00	40.84	342.73	3.77
Other Income	0.55	122.00	12.78	244.31	27.45
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	9.07	463.00	371.35	-162.68	528.56
Provision for Tax	1.48	49.00	83.14	209.13	141.21
Profit after Tax	7.59	414.00	288.22	-371.81	387.35

	Kabra Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	29.62	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	0.12	1,712.00	202.03	5,044.14	42.40
Current Liabilities	56.54	1,622.00	835.87	4,758.28	230.82
Total Liabilities	25.23	8,100.00	1,451.43	15,513.53	1,549.26

	Kabra Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	2.18	5,343.00	519.60	10,211.52	1,026.85
Current Assets	83.92	2,606.00	1,681.81	7,191.66	881.27
Total Assets	25.23	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	0.44	1,859.00	393.17	4,720.27	8.18
Net Current Assets	27.38	984.00	845.94	2,433.38	650.46
Contingent Liabilities	0.49	770.26	12.25	99.76	15.38

	Kabra Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-4.71	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-0.05	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	23.39	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	18.63	-396.00	54.56	-25.99	155.52

	Kabra Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-7.78	4.07	26.97	6.61	20.14
ROE (%)	27.30	8.38	29.77	-3.85	25.18
ROA (%)	13.61	4.94	24.77	-2.21	21.93
EBIT Margin (%)	6.47	15.32	20.63	1.66	34.54
Net Margin (%)	5.73	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Kabra Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	821.73	18.37	46.65	0.78	40.90
EBIT Growth (%)	608.88	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	855.12	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	441.96	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	1,780.51	29.77	42.49	2.28	94.96

	Kabra Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	6.40	79.96	104.15	-91.43	70.64
Price / Book Value	1.53	6.33	22.71	3.57	15.78
Dividend Yield (%)	0.00	0.00	0.08	0.00	0.08
EV/EBITDA	3.22	43.17	67.52	32.42	49.84
Market Cap (₹ Cr)	--	23,064.69	0.00	29,731.27	19,988.69

	Kabra Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	0.31	0.11	0.53	0.01
Short term debt to equity ratio	0.02	0.11	0.54	0.12	0.02
Current Ratio	1.48	1.61	2.01	1.51	3.82
Quick Ratio	1.48	1.06	1.14	0.87	2.82
Interest Coverage	413.05	3.13	10.09	0.53	141.16

	Kabra Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	53.70	16.50	26.28	23.44	24.80
Asset Turnover	2.36	0.43	1.66	0.55	0.83
Receivable days	--	60.36	47.59	77.05	90.06
Inventory Days	--	64.42	62.58	77.13	61.02
Payable days	--	218.94	228.78	173.49	96.06
Cash Conversion Cycle	--	-94.15	-118.62	-19.30	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.